IMAGINE PHARMA LLC
Novel polypeptide and oral delivery platforms for therapeutic and regenerative medicine
- Sector
- Biotech
- Headquarters
- PITTSBURGH, PA
- Latest Form D
- $300K, Jan 2023
- Total capital
- $350K
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $350K
- 3 Form D · last Jan 2023
- 46 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 17 pending · first 2020
- Rank in peer group#339 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$300K
- Private capital raisedForm D · SEC · 1st filing$50K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#339 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Ngoc ThaiResearcherExecutive OfficerLinked by 3 patents
- Kristin NevinsExecutive OfficerNamed in SEC Form D filings
- Santiago PujadasExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 20- PendingCompositions And Methods For Oral DeliveryUSPTOApplication 18683324
- PendingDietary Supplements, Compositions, And Uses Thereof For Increasing Telomerase Activity And Extending Telomere LengthUSPTOApplication 19092807
- GrantedComposition and Methods for Producing Insulin Producing Islet CellsUSPTOUS 12,290,536
Show all 20 patent records
- Compositions And Methods For Oral DeliveryDec 25, 2025 · Application 18683324Pending
- Dietary Supplements, Compositions, And Uses Thereof For Increasing Telomerase Activity And Extending Telomere LengthOct 30, 2025 · Application 19092807Pending
- Composition and Methods for Producing Insulin Producing Islet CellsMay 6, 2025 · US 12,290,536Granted
- Compositions And Methods For Treating WoundsJan 18, 2024 · Application 18028104Pending
- Compositions And Methods For Treating Diabetes, Hypertension And HypercholesterolemiaAug 24, 2023 · Application 17892224Pending
- Methods And Compositions For Modulating Endothelial Cell DysfunctionJul 6, 2023 · Application 16960505Pending
- Compositions And Methods For Treating Diabetes, Hypertension And HypercholesterolemiaMar 28, 2023 · US 11,612,637Granted
- Compositions And Methods For Treating Diabetes, Hypertension And HypercholesterolemiaAug 25, 2020 · US 10,751,384Granted
- Compositions And Methods For Treating WoundsApplication PCTUS2021062281Pending
- Compositions And Methods For Propagating Insulin-producing Islet Cells And Therapeutic Uses ThereofApplication PCTUS2019038305Pending
- Insulin Producing Islet Progenitor Cells, And Isolation Activation, Propagation, And Therapeutic Uses ThereofApplication 62689780Pending
- Polypeptides And Compositions For Oral Administration And Methods Of Use ThereofApplication PCTUS2025056765Pending
- Compositions And Methods For Propogating Insulin And Glucagon Secreting Cells From Type 1 Diabetic Pancreatic Tissue And Therapeutic Uses ThereofApplication 18294669Pending
- Peptide Conjugates For Oral DeliveryApplication 63839404Pending
- Nanobody-peptide Conjugates To Produce Orally Bioavailable ProteinsApplication 63839371Pending
- Dietary Supplements, Compositions, And Uses Thereof For Increasing Telomerase Activity And Extending Telomere LengthApplication PCTUS2025021652Pending
- Compositions For Oral Administration And Methods Of Use ThereofApplication 63724239Pending
- Dietary Supplements, Compositions, And Uses Thereof For Increasing Telomerase Activity And Extending Telomere LengthApplication 63571675Pending
- Compositions And Methods For Oral AdministrationApplication PCTUS2022081277Pending
- Compositions And Methods For Propogating Insulin And Glucagon Secreting Cells From Type 1 Diabetic Pancreatic Tissue And Therapeutic Uses ThereofApplication PCTUS2022044024Pending
Related companies, and why
- AVENUE THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Medexus Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
- Essential Remedium Corp.Similar federal contract value in Biotech · null in contracts
- St. James Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- InGel Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Sernova Biotherapeutics Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .